stockrow
Friday 6 November 2026
Export DFTX’s income statement to Excel — free account
Definium Therapeutics, Inc.
DFTX Healthcare Biotechnology
- EPS
- −188.0%
- Free cash flow
- −78.3%
- Total debt
- −11.5%
Quarter to June 2026, against a year earlier
33.27
2.91
+9.58%
Follow DFTX
Alert me
Definium Therapeutics, Inc. (DFTX) Book value per share
Definium Therapeutics, Inc.'s book value per share at the end of fiscal 2025 was 3.7×, up 8.57% from 3.4× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 8.3×. Over the past ten years it has ranged from 0.0× (fiscal 2019) to 12.5× (fiscal 2017); the current reading is higher than 50% of that period. Definium Therapeutics, Inc. ranks 90th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 3.7× | 8.57% |
| FY2024 | 3.4× | 71.73% |
| FY2023 | 2.0× | (59.20%) |
| FY2022 | 4.9× | (11.71%) |
| FY2021 | 5.5× | 29.66% |
| FY2020 | 4.3× | — |
| FY2019 | 0.0× | — |
| FY2018 | 8.3× | (33.60%) |
| FY2017 | 12.5× | 15,872.89% |
| FY2016 | 0.1× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 8.3× | 223.81% |
| Mar 2026 | 2.6× | (31.10%) |
| Dec 2025 | 3.7× | 144.66% |
| Sep 2025 | 1.5× | (30.00%) |
| 25 more quarters | Free account |
Against its own ten years
Low 0.0×
High 12.5×
Ten-year median
4.0×
Current reading's percentile
50
Book value per share against peers
| Company | Book value per share |
|---|---|
| DNTH Dianthus Therapeutics, Inc. compare | 21.6× |
| EWTX Edgewise Therapeutics, Inc. compare | 15.0× |
| XENE Xenon Pharmaceuticals Inc. compare | 12.5× |
| DFTX Definium Therapeutics, Inc. | 8.3× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 8.0× |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 6.6× |
| RLAY Relay Therapeutics, Inc. compare | 3.7× |
| ABCL AbCellera Biologics Inc. compare | 2.9× |
| ERAS Erasca, Inc. compare | 1.2× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))